BioForce Announces New Sale to Harvard Medical School

BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB), announced today the completion of a Nano eNabler(TM) system sale to the Technology & Engineering Center at Harvard Medical School. Funding for the purchase was provided by an award from the National Human Genome Research Institute (NHGRI).

"The completion of this sale marks an important event for BioForce as the company develops this new and exciting technology," notes Kerry Frey, chief operating officer of BioForce Nanosciences. "We are working to promote the unique opportunities that the Nano eNabler technology provides to assist researchers working with smaller platforms."

Dale Larson, Director of the Technology and Engineering Center is leading the use of the Nano eNabler system. His group is utilizing the system to print very small femtoliter volumes of biomolecules onto specially developed nanohole array sensors with sub-micron dimensions. This technology is being developed for use in drug discovery and development, biomarker screening, diagnostic assays, and homeland security applications. The nanohole array sensing technology is a label-free detection system that is very sensitive and highly multiplexed. The Nano eNabler system enables the printing of many different capture agents on their chip, allowing researchers to simultaneously study many different binding interactions from one sample on one chip.

Michael Lynch, BioForce product manager for the Nano eNabler system notes, "I am very pleased to be working with this key group of Harvard Medical School researchers. BioForce is focused on marketing this unique printing technology to researchers working in a variety of areas where these smaller micron and sub-micron dimensions are standard. As biosensors and nanosensors move from academic R&D into commercial product development, our printing technology will be called upon to address the needs of the production environment."

About BioForce Nanosciences, Inc.

BioForce Nanosciences is a nanotechnology tools and applications company, providing innovative and practical products that support the growth of the nanotechnology industry. BioForce has spent more than a decade on invention, research, and development of patented and patent-pending nanotechnology products. The core technology is the Nano eNabler(TM) bench-top molecular printer, a portal to new opportunities in nanotechnology. The Nano eNabler printing system opens the door to new and important applications in the biomedical and life sciences markets that lead to improved quality of life. BioForce continues to target inventions that further expand the reach of its proprietary technology and expand its robust patent, trademark, and IP portfolio.

BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) Company, brings inventions to the marketplace that complement existing innovations, licensing and acquisitions. BioForce is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB).

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.